Page 332 - Read Online
P. 332

Varikuti et al. Vessel Plus 2020;4:28  I  http://dx.doi.org/10.20517/2574-1209.2020.27                                               Page 11 of 20

               Role of the VE in Chagas disease
               T. cruzi infects various types of cells including cardiac myocytes, GI-tract, smooth muscle cells, and the
               VE [95,153] . The VE plays a key role in the dissemination of T. cruzi, as parasites engage ECs during the initial
               stages of infection [85,86] . As the infection progresses, VE release inflammatory molecules by direct physical
               disruption of ECs, and parasites undergo trans-endothelial migration with the help of the parasite protease,
               cruzipain [85,87,88] . Cruzipain cleaves the human kininogen into bradykinin, an inflammatory mediator
               of endothelial permeability [85,154,155] . Studies have shown that T. cruzi induces ECs release of vasoactive
               molecules endothelin-1, pro-inflammatory cytokines (IL-1β, IL-6, and TNF-a), and thromboxane A2,
               which trigger the production of iNOS and nitrosative stress [89-92] . Moreover, increased levels of TNF-a
                                                                    [92]
               exacerbate endothelial COX-2/TXA2/TP/superoxide signaling . The infection of T. cruzi also activates the
                                                                                                       [95]
               NF-kB that accumulates in the nucleus and activates many genes specific to endothelial pathophysiology .
               In addition to the vascular damage, T. cruzi invades VE through the secretion of neuraminidase that
               removes sialic acid from the infected ECs [156,157] . Collectively, all of these factors compromise the activity
               of ECs and cause vasculopathy, as demonstrated by vasospasm, focal ischemia, reduction in the blood
               flow, increased platelet aggregation, and elevated levels of thromboxane A (2) and endothelin-1 [89,158,159] .
               Studies have shown that T. cruzi-infected ECs secrete endothelin-1 and interleukin-1beta (IL-1β), which
               activate extracellular signal-regulated kinases 1 and 2 (ERK1/2) and NF-kB, resulting in the expression
               of cyclin-D1 in uninfected smooth muscle cells [93-95] . The activation of these pathways involved in the
               interaction between T. cruzi and the VE are likely to play a major role in the inflammatory responses after
               vascular injury and endothelial dysfunction and could be potential targets for therapies to control parasite
               dissemination [65,85] .

               It is estimated that 10%-30% of patients infected with T. cruzi progress to the chronic stage manifested
               by cardiomyopathy and prothrombotic/inflammatory status [160] . Pathophysiological mechanisms such as
               activation of the endothelium and microvascular alterations occur during the cardiac damage. It is known
               that thromboxane A2 increases platelet aggregation and that inhibiting the formation of thromboxane A2
               by aspirin alters the course of Chagas disease in both acute and chronic phases [161] . Benznidazole, a widely
               used drug for the treatment of Chagas disease, also acts by preventing endothelial damage caused by
               T. cruzi [162] . Cholesterol-lowering drugs such as simvastatin have been shown to decrease the endothelial
               activation and, in combination with benznidazole, improve the pathophysiological condition of chronic
               Chagas disease patients [163] . Recent discoveries have provided insights into how T. cruzi escapes the BBB
               and rapidly migrates across the ECs without disrupting the integrity of the monolayer or altering the
                                     [85]
               permeability. Coates et al.  identified that this process is facilitated by bradykinin and CCL2, which may
               be considered in the development of new therapeutic strategies for Chagas disease.

               Role of exosomes in Chagas disease
               Parasite and host cell exosomes play a role in the pathogenesis in Chagas disease. The release of an elevated
               number of exosomes is essential for host-parasite interaction, intercellular communication, and enhanced
               parasite survival [120] . The infection of T. cruzi induces blood cells to release exosomes through a Ca -
                                                                                                        2+
               dependent manner [164] . The released exosomes protect extracellular trypomastigotes from complement-
               mediated lysis by binding to C3 convertase on the T. cruzi surface and inhibiting C3 cleavage [115-117] .
               Exosomes also aid the parasites to invade the host cells through the expression of TGF-β. The
               communication between cells takes place through the release of exosomal contents including cytokines,
               peptides, hormones, microRNA, and numerous bioactive substances, which act as a function of innate
               immunity [165,166] . Exosomes released by T. cruzi promote cell invasion and parasite survival by modulating
               the innate immune system and producing several virulence factors including the glycoprotein 85 (gp85),
               trans-sialidase, phosphatase, and the soluble proteins [116,119,120,167] . Thus, the exosomes released by the host
               cells and parasites during infection play a vital role in the invasion of the innate immune system, parasite
               survival, and the establishment of infection in Chagas disease.
   327   328   329   330   331   332   333   334   335   336   337